Access Pharmaceuticals, Inc. (ACCP.OB) Signs Major Distribution Agreement with BioScrip

QualityStocks would like to highlight Access Pharmaceuticals, Inc. (OTCBB: ACCP). Access Pharmaceuticals is an emerging biopharmaceutical company that develops and commercializes proprietary products for the treatment and supportive care of cancer patients. Access' products include ProLindac™, currently in Phase II clinical testing of patients with ovarian cancer, and MuGard™ for the management of patients with mucositis.

In the company’s news yesterday,

Access Pharmaceuticals announced the signing of an agreement with BioScrip (NASDAQ: BIOS) for the distribution of MuGard, the lead product of Access. MuGard is an FDA approved oral wound rinse for the management of oral mucositis, a debilitating side effect of radiotherapy and/or chemotherapy. The agreement provides for the distribution of MuGuard through BioScrip’s nationwide distribution platform, including 110 BioScrip specialty pharmacies. It also allows Access to leverage BioScrip’s extensive physician relationships, and provides for mail distribution and a diversified payor network.

BioScrip is a national provider of specialty pharmacy and home care products and services, working with patients, physicians, hospitals, healthcare payors, and pharmaceutical manufacturers. Access VP of Sales and Marketing, Frank Jacobucci, spoke of the significance of the BioScrip agreement. “As one of the largest, top-tier players in this space, BioScrip is well-established, reputable and focused on tailoring its programs to best fit and meet product manufacturers, provider and payers and patients’ pharmacy service needs. In addition to the varied services that they will provide us, this partnership also results in multiple delivery options for patients in need of MuGard, including overnight delivery, home delivery and live retail pharmacy sites in the top metropolitan areas. We believe offering various methods of receiving MuGard can significantly increase patient compliance and ultimately provide an important additional weapon to help improve the treatment outcome.”

Access CEO, Jeffrey Davis, said, “Signing a strong specialty distribution partner is a critical milestone for a successful entrance into the US market. With its significant resources, deep capabilities and strong commitment to cancer patients, BioScrip is an ideal partner to have in place as we continue executing on our global-commercialization strategy for MuGard.”

BioScrip VP of Trade Relations and Business Development, Scott Friedman, said, “BioScrip is proud to have been selected by Access to be its exclusive distribution and service partner for MuGard. Our vast clinical, sales and operational specialty pharmacy assets, combined with our deep oncology experience, put us in a unique position to provide services to the patient, manufacturer, provider and payor communities.”

About QualityStocks

QualityStocks, based in Scottsdale, Arizona is a free service that collects data from hundreds Small-Cap and Micro-Cap online Investment Newsletters into one Free Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their advertising efforts and now has over 750,000+ subscribers that receive The Daily Stock Newsletters.

To sign up for “The QualityStocks Daily Newsletter” please visit http://www.qualitystocks.net/

Please see disclaimer on QualityStocks website: http://Disclaimer.QualityStocks.net 

Forward-Looking Statement:

This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.